Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bio-Techne (TECH) EBITDA (2016 - 2026)

Bio-Techne has reported EBITDA over the past 17 years, most recently at $40.1 million for Q4 2025.

  • For Q4 2025, EBITDA rose 329.51% year-over-year to $40.1 million; the TTM value through Dec 2025 reached $104.4 million, down 23.31%, while the annual FY2025 figure was $91.8 million, 41.08% down from the prior year.
  • EBITDA for Q4 2025 was $40.1 million at Bio-Techne, up from $33.7 million in the prior quarter.
  • Over five years, EBITDA peaked at $84.9 million in Q4 2021 and troughed at $4.5 million in Q2 2025.
  • A 5-year average of $46.9 million and a median of $41.6 million in 2022 define the central range for EBITDA.
  • On a YoY basis, EBITDA climbed as much as 329.51% in 2025 and fell as far as 88.04% in 2025.
  • Year by year, EBITDA stood at $84.9 million in 2021, then fell by 21.46% to $66.7 million in 2022, then tumbled by 37.29% to $41.8 million in 2023, then tumbled by 77.7% to $9.3 million in 2024, then surged by 329.51% to $40.1 million in 2025.
  • Business Quant data shows EBITDA for TECH at $40.1 million in Q4 2025, $33.7 million in Q3 2025, and $4.5 million in Q2 2025.